Shots:
- PerkinElmer to acquire IDS in all cash transactions for ~$155M. The transaction is expected to be completed in Q3’21
- The acquisition will allow PerkinElmer to foster its overall Diagnostics business and specifically its immunodiagnostics segment
- The acquisition will integrate PerkinElmer’s channel expertise and testing capabilities with IDS’ chemiluminescence products in endocrinology, autoimmunity, and infectious diseases to better serve customers across the globe
Click here to read full press release/ article | Ref: Businesswire | Image: Wikipedia
The post PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M first appeared on PharmaShots.
